Erratum

Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics

Meyling Cheok, Wenjian Yang, Gianluigi Zaza, Qing Cheng, John C. Panetta, Ching-Hon Pui, James R. Downing, Mary V. Relling and William E. Evans

Original citation: J. Clin. Invest.115:110–117(2004). doi:10.1172/JCI22477

Citation for this erratum: J. Clin. Invest.115:477 (2005). doi:10.1172/JCI22477E1

During preparation of this manuscript for publication, errors were introduced into the abstract and introduction. The second sentence of the abstract incorrectly included the phrase “fewer than.” The sentence should read:

“We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (greater than 50 chromosomes) ALL.”

The third sentence of the introduction also incorrectly stated “fewer than.” This sentence should read:

“Subtypes with a relatively unfavorable prognosis on many treatment protocols include T-lineage ALL (T-ALL) and ALL with rearranged MLL genes or with BCR-ABL gene fusion, whereas ALL with either TEL-AML1 or E2A-PBX1 gene fusions, or hyperdiploid karyotypes (greater than 50 chromosomes), have a relatively good prognosis with most treatment protocols . . .”

We regret these errors.